Chungnam National University Sejong Hospital Begins Patient Treatments with ViewRay's MRIdian Linac

Rhea-AI Summary

ViewRay, Inc. (Nasdaq: VRAY) announced that Chungnam National University Sejong Hospital in South Korea has commenced patient treatments using the MRIdian MRI-Guided Therapy System. This advanced radiation therapy technology allows for real-time tumor tracking and adaptive treatment, enhancing patient safety and treatment efficacy. As of now, there are 39 MRIdian systems installed globally, having treated over 10,000 patients. The integration of MRIdian supports CNUH's commitment to providing state-of-the-art cancer care.

Positive

• Chungnam National University Sejong Hospital begins using MRIdian, enhancing treatment capabilities.
• MRIdian offers real-time adaptive therapy, improving patient safety and treatment efficacy.
• 39 MRIdian systems are installed worldwide, showing increasing adoption.

Negative

• None.

CLEVELAND, Sept. 24, 2020 /PRNewswire/ -- ViewRay, Inc. (Nasdaq: VRAY) announced today that Chungnam National University Sejong Hospital in Sejong, South Korea has begun patient treatments with the MRIdian^® MRI-Guided Therapy System, a cutting-edge radiation therapy device that combines the latest innovations in precision radiation delivery and ground-breaking MRI-guidance.

Unlike conventional radiation therapy systems, MRIdian combines an MRI system with a radiation therapy system. Together with other technical innovations, this offers advantages for the delivery of safe and effective radiotherapy, including the ability to see the tumor and surrounding tissue during treatment, adaptation of the therapy in response to changes in patient anatomy and tumor size between treatments, continuous tracking of the tumor during treatment, and automatic pausing of the radiation if the tumor moves outside of the boundary. As a result, the system is able to deliver high-dose radiation to the tumor while protecting the surrounding healthy tissue from damage.      

"We're excited to add MRIdian to our cancer treatment offerings and expand our capabilities to include MRI-guided and real-time adaptive therapy," said Young II Kim, M.D., Radiation Oncologist, at Chungnam National University Sejong Hospital. "The ability to see what we're treating while we're treating it is like no other, and then to be able to adapt the treatment on the fly to address changes or constraints is unprecedented. We're proud to bring this life changing therapy to our patients."

Chungnam National University Hospital (CNUH) was founded in 1972 as the first training hospital in the central area of Korea. CNUH is known for its remarkable achievements and incredible growth and development over the years. CNUH strives to continually advance its healthcare services with state-of-the-art equipment and world-class medical professionals. The construction of the Chungnam National University Sejong Hospital in 2019 furthers its commitment to achieving continuous growth as a hospital equipped with a world-class healthcare system. The addition of MRIdian brings cutting-edge MRI-guided radiation therapy to its offerings.

"We're pleased to welcome Chungnam National University Sejong Hospital to the growing list of hospitals integrating MRIdian into their radiation oncology programs," said Paul Ziegler, Senior Vice President of Sales and Marketing at ViewRay. "The addition of MRI-guided radiation therapy with MRIdian supports the hospital's commitment to offer world-class care to its patients."

Currently 39 MRIdian systems are installed at hospitals around the world, where they are used to treat a wide variety of solid tumors and are the focus of numerous ongoing research efforts. MRIdian has been the subject of hundreds of peer-reviewed publications, scientific meeting abstracts and presentations. More than 10,000 patients have been treated with MRIdian. For a list of treatment centers, please visit: https://viewray.com/mridian-locator.

About ViewRay
ViewRay, Inc. (Nasdaq: VRAY), designs, manufactures and markets the MRIdian^® radiation therapy system. MRIdian is built upon a proprietary high-definition MR imaging system designed from the ground up to address the unique challenges and clinical workflow for advanced radiation oncology. Unlike MR systems used in diagnostic radiology, MRIdian's high-definition MR was purpose built to address specific challenges, including beam distortion, skin toxicity, and other concerns that potentially may arise when high magnetic fields interact with radiation beams. ViewRay and MRIdian are registered trademarks of ViewRay, Inc.

Forward-Looking Statements
This press release contains forward-looking statements within the meaning of Section 27A of the Private Securities Litigation Reform Act. Statements in this press release that are not purely historical are forward-looking statements. Such forward-looking statements include, among other things, the rate of new orders, upgrades, and installations, ViewRay's anticipated future operating and financial performance, and ViewRay's conference calls to discuss its quarterly results. Actual results could differ from those projected in any forward-looking statements due to numerous factors. Such factors include, among others, the ability to commercialize MRIdian Linac System, demand for ViewRay's products, the ability to convert backlog into revenue, the timing of delivery of ViewRay's products, the timing, length, and severity of the recent COVID-19 (coronavirus) pandemic, including its impacts across our businesses on demand, operations and our global supply chains, the results and other uncertainties associated with clinical trials, the ability to raise the additional funding needed to continue to pursue ViewRay's business and product development plans, the inherent uncertainties associated with developing new products or technologies, competition in the industry in which ViewRay operates, and overall market conditions. For a further description of the risks and uncertainties that could cause actual results to differ from those expressed in these forward-looking statements, as well as risks relating to ViewRay's business in general, see ViewRay's current and future reports filed with the Securities and Exchange Commission, including its Annual Report on Form 10-K for the fiscal year ended December 31, 2019 and its Quarterly Reports on Form 10-Q, as updated periodically with the company's other filings with the SEC. These forward-looking statements are made as of the date of this press release, and ViewRay assumes no obligation to update the forward-looking statements, or to update the reasons why actual results could differ from those projected in the forward-looking statements, except as required by law.

 

View original content to download multimedia:http://www.prnewswire.com/news-releases/chungnam-national-university-sejong-hospital-begins-patient-treatments-with-viewrays-mridian-linac-301137239.html

SOURCE ViewRay, Inc.

FAQ

What is MRIdian and how does it improve cancer treatment at Chungnam National University Sejong Hospital?

MRIdian is an MRI-guided radiation therapy system that allows for real-time tumor tracking and adaptive treatment, enhancing safety and efficacy during cancer treatments.

How many MRIdian systems are currently in use worldwide?

Currently, there are 39 MRIdian systems installed at hospitals around the world.

What impact does the MRIdian system have on patient safety?

The MRIdian system improves patient safety by allowing for high-dose radiation delivery to tumors while protecting surrounding healthy tissue.

How many patients have been treated with the MRIdian system to date?

More than 10,000 patients have been treated with the MRIdian system globally.